Key facts
- This page summarizes Pivotal bioVenture Partners Fund I, L.P.'s Form 4 filing for Inozyme Pharma, Inc. (INZY).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 03 Aug 2023, 20:13.
Pivotal bioVenture Partners Fund I, L.P. - 01 Aug 2023 Form 4 Insider Report for Inozyme Pharma, Inc. (INZY)
- Reporting relationship
- Director
- Issuer ticker
- INZY
- Reported as of
- 01 Aug 2023
- Net transaction value
- +$3,999,998
- SEC form
- 4
- Accepted by SEC
- 03 Aug 2023, 20:13:28 UTC
- Prior SEC filing
- 20 Apr 2022
- Next SEC filing
- 05 Nov 2025
- Source filing
- View source filing
- Reporting owner signature
- Pivotal bioVenture Partners Fund I, L.P. By: Robert Hopfner Managing Partner /s/ Robert Hopfner
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Pivotal bioVenture Partners Fund I, L.P. filed Form 4 for Inozyme Pharma, Inc. (INZY) on 03 Aug 2023.
Change
- Previous filing in this sequence was filed on 20 Apr 2022.
- Current net transaction value: +$3,999,998.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
INZY
transaction
Common Stock
Purchase
- Transaction value
- $571,430
- Shares
- +119,048
- Change %
- +4.2%
- Price
- $4.80
- Shares after
- 2,923,110
- Date
- 01 Aug 2023
- Ownership
- See footnotes
- Footnotes
- F1, F2, F3
INZY
transaction
Common Stock
Purchase
- Transaction value
- $3,428,568
- Shares
- +714,285
- Change %
- +83%
- Price
- $4.80
- Shares after
- 1,571,741
- Date
- 01 Aug 2023
- Ownership
- See footnotes
- Footnotes
- F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Held directly by Pivotal bioVenture Partners Fund I, L.P ("Pivotal I").
Footnote F2
The general partner of Pivotal I and Pivotal bioVenture Partners Fund II, L.P ("Pivotal II") is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner"). The Ultimate General Partner is wholly-owned by Pivotal Partners Ltd ("Pivotal Partners"). Pivotal Partners is wholly-owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly-owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings LImited ("NFIHL"), which is wholly owned by Nan Fung Group Holdings Limited ("NFGHL").
Footnote F3
The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such person's and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein.
Footnote F4
Held by Pivotal II.